Asymptomatic Carotid Artery Stenosis
Conditions
Keywords
Asymptomatic carotid stenosis, Carotid stenting, Best medical therapy, Randomized controlled trial, Stroke prevention, Endovascular treatment, Carotid artery disease, Ischemic stroke
Brief summary
This study is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the safety and efficacy of endovascular stenting combined with optimal medical therapy versus optimal medical therapy alone in patients with asymptomatic severe stenosis (70-99%) of the internal carotid artery. The study plans to enroll 982 patients aged 40-80 years who have had no ipsilateral carotid artery-related neurological symptoms in the past six months and who have declined carotid endarterectomy. The primary endpoints include stroke, myocardial infarction, or death within 30 days post-procedure/enrollment, as well as the incidence of ipsilateral stroke from 30 days to one year post-procedure/enrollment. Secondary endpoints include procedural success rate, restenosis rate, changes in cognitive function, and others. The study results will provide high-level evidence-based medical evidence for the treatment selection of patients with asymptomatic carotid artery stenosis.
Detailed description
This multicenter, prospective, open-label, randomized controlled trial with blinded endpoint assessment aims to evaluate the safety and efficacy of endovascular stenting combined with best medical therapy (BMT) versus BMT alone in patients with asymptomatic severe stenosis (70-99%) of the internal carotid artery (ICA). The study will enroll 982 participants aged 40-80 years who have no history of ipsilateral transient ischemic attack (TIA), stroke, or related neurological symptoms within the past 6 months and have declined carotid endarterectomy. The primary objective is to determine whether stenting reduces the composite risk of stroke, myocardial infarction, or death within 30 days post-procedure/enrollment, as well as ipsilateral stroke from 30 days to 1 year. Secondary objectives include assessing procedural success, restenosis rates, cognitive outcomes (measured by Montreal Cognitive Assessment \[MoCA\] and Mini-Mental State Examination \[MMSE\]), and long-term clinical outcomes. The trial will be conducted across multiple centers in China, led by Beijing Tiantan Hospital, Capital Medical University. Participants will be randomly assigned (1:1) via a computer-generated stratified randomization scheme to either the intervention group (endovascular stenting plus BMT) or the control group (BMT alone). BMT includes antiplatelet therapy, lipid-lowering agents, blood pressure control, and management of other cardiocerebrovascular risk factors. Endpoint adjudication will be performed by an independent blinded clinical events committee to minimize bias. Eligible participants must have severe ICA origin stenosis confirmed by ultrasound, computed tomography angiography (CTA), or digital subtraction angiography (DSA), with contralateral ICA stenosis \<70%. Key exclusion criteria include recent symptomatic stenosis, intracranial hemorrhage within 1 year, severe cardiopulmonary comorbidities, contraindications to antiplatelet/anticoagulant therapy, life expectancy \<5 years, or anatomical challenges (e.g., Type III aortic arch, severe vascular tortuosity/calcification). Imaging exclusions focus on technical feasibility and safety, such as tandem intracranial stenosis or distal lesions more severe than the target stenosis. The primary endpoints are the 30-day composite rate of stroke, myocardial infarction, or death, and the incidence of ipsilateral stroke between 30 days and 1 year. Secondary endpoints include technical success (defined as residual stenosis \<30% with Thrombolysis in Myocardial Infarction \[TIMI\] grade 3 flow post-procedure), 30-day and 12-month mortality, restenosis rates, and cognitive changes. Statistical analysis will follow the intention-to-treat principle, with Kaplan-Meier survival analysis and log-rank tests for primary outcomes. Cox proportional hazards models will estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Sensitivity analyses will use per-protocol and as-treated populations. The study duration is scheduled from August 2024 to July 2028, including a 12-month follow-up period. Ethical approval will be obtained from all participating centers, and the trial will adhere to the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.
Interventions
PROCEDUREEndovascular treatment
Participants will receive carotid artery stenting as the primary intervention. The procedure will be performed via femoral artery access (radial access allowed for anatomically challenging cases) with mandatory use of an embolic protection device (EPD). Stent selection and EPD type will be determined by the operator based on lesion characteristics. Pre-procedural dual antiplatelet therapy (DAPT: aspirin 100 mg/day + clopidogrel 75 mg/day) will be administered for ≥3-5 days. Post-procedural DAPT will continue for 3 months, transitioning to aspirin monotherapy (100 mg/day) thereafter. Statins and risk factor management (blood pressure、LDL-C, glycemic control) will align with standardized protocols.
DRUGBest medical treatment
Participants will receive intensive medical management, including aspirin (75-325 mg/day) or alternative antiplatelet agents (clopidogrel/dipyridamole) for intolerance. Statin therapy and risk factor control targets (blood pressure, lipids, glucose, lifestyle) will mirror the experimental group. Both groups will undergo regular follow-up for adherence monitoring.
Sponsors
Beijing Tiantan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age 40-80 years 2. Severe asymptomatic internal carotid artery stenosis (70-99%) confirmed by ultrasound/CTA/DSA 3. Contralateral ICA stenosis \<70% 4. No TIA/stroke related to target lesion in past 6 months 5. Declined carotid endarterectomy 6. Willing to complete 12-month follow-up 7. Signed informed consent by participant/legal representative
Exclusion criteria
1. symptomatic internal carotid artery stenosis in the past 6 months 2. Spontaneous intracranial hemorrhage in nearly one year 3. Patients with larger intracranial aneurysms (diameter \>5 mm) who cannot undergo prior or concurrent treatment 4. Chronic occlusion without obvious symptoms of cerebral ischemic attack 5. Patients with transient or permanent neurological deficit resulting from Neurological deficits mimicking TIA/stroke from TIA or stroke 6. Common carotid artery ostial lesion 7. Tandem lesions with severe stenosis of the ipsilateral intracranial artery 8. Patients with severe dementia 9. Internal carotid artery dissection 10. Internal carotid artery aneurysm 11. Myocardial infarction within 30 days 12. Ejection fraction \<30% or New York Heart Association (NYHA) functional class III or higher; unstable angina, characterized by angina at rest with electrocardiogram changes 13. Cardiogenic embolism, including left ventricular aneurysm, intraluminal filling defects, cardiomyopathy, aortic or mitral valve-prosthetic heart valve, calcified aortic stenosis, infective endocarditis 14. Mitral stenosis, atrial septal defect, atrial septal aneurysm or left chamber myxoma 15. Two or more proximal or main coronary artery stenosis 70%, untreated or recanable 16. Platelets \<5 \* 104 / uL, INR\> 1.5, bleeding time\> 1min or heparin-related thrombocytopenia; heparin is a contraindication to antiplatelet drugs; coagulopathy 17. Poor controlled diabetes mellitus, fasting blood glucose\> 22 mmol/L and ketone body\>+2 18. Malignant tumor or respiratory insufficiency, and a life expectancy of \<5 years 19. Severe liver and kidney function impairment, ALT\> 3 times the upper limit of normal value or AST\> 3 times the upper limit of normal value, blood creatinine increase\> 2 times the upper limit of normal value 20. Contrast allergy 21. Other general anesthesia operations are required during the same period 22. Pregnant or lactating women 23. The patient does not attend the clinical trial of other drug or medical device before enrollment 24. The investigator is not considered fit to participate in this clinical study Imaging
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy endpoint | Within 30 days/ between 30 days and 12 months post-enrollment or post-procedure | The primary outcome was a composite of any stroke, myocardial infarction (MI), or all-cause mortality within 30 days post-enrollment or post-procedure, plus ipsilateral stroke between 30 days and 12 months post-enrollment/procedure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of myocardial infarction | Within 30 days after surgery or within 30 days of enrollment | Incidence of myocardial infarction within 30 days after surgery or within 30 days of enrollment |
| Incidence of ipsilateral stroke | Within 30 days after surgery or within 30 days of enrollment | Incidence of ipsilateral stroke within 30 days after surgery or within 30 days of enrollment |
| Incidence of bilateral stroke | Within 30 days after surgery or within 30 days of enrollment | Incidence of bilateral stroke within 30 days after surgery or within 30 days of enrollment |
| The incidence of all-cause death | Within 30 days after surgery or within 30 days of enrollment | The incidence of all-cause death after surgery or within 30 days of enrollment |
| Success rate of surgical technique | Surgery completed | Success rate of surgical technique (defined as final residual stenosis \<30%,TIMI grade 3, no dissection or thrombosis after endovascular treatment) |
| Cognitive improvement (MMSE scale) | 30 days after surgery or within 30 days of enrollment | Cognitive function assessment (MMSE scale) after surgery or within 30 days of enrollment (optional) |
| Rate of internal carotid artery restenosis | 12 months after surgery or enrollment | Rate of internal carotid artery restenosis at 12 months after surgery or enrollment; (Internal carotid artery restenosis definition: Restenosis ≥50% after internal carotid artery stent implantation, peak contraction velocity ratio \[PSVR\]≥2.0) |
| Improvement in cognitive function (MMSE scale) | 12 months after surgery or enrollment | Improvement in cognitive function (MMSE scale) at 12 months after surgery or enrollment (optional) |
| Cognitive function improvement (MoCA scale) | Within 30 days after surgery or within 30 days of enrollment | Cognitive function assessment at 30 days after surgery or within 30 days of enrollment (MoCA scale) (optional) |
Countries
China
Contacts
Primary ContactDapeng Sun, MD
Outcome results
None listed